TY - JOUR
T1 - The mechanism of sirtuin 2–mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease
AU - de Oliveira, Rita Machado
AU - Vicente Miranda, Hugo
AU - Francelle, Laetitia
AU - Pinho, Raquel
AU - Szegö, Éva M.
AU - Martinho, Renato
AU - Munari, Francesca
AU - Lázaro, Diana F.
AU - Moniot, Sébastien
AU - Guerreiro, Patrícia
AU - Fonseca, Luis
AU - Marijanovic, Zrinka
AU - Antas, Pedro
AU - Gerhardt, Ellen
AU - Enguita, Francisco Javier
AU - Fauvet, Bruno
AU - Penque, Deborah
AU - Pais, Teresa Faria
AU - Tong, Qiang
AU - Becker, Stefan
AU - Kügler, Sebastian
AU - Lashuel, Hilal Ahmed
AU - Steegborn, Clemens
AU - Zweckstetter, Markus
AU - Outeiro, Tiago Fleming
N1 - Publisher Copyright:
© 2017 de Oliveira et al.
PY - 2017/3/3
Y1 - 2017/3/3
N2 - Sirtuin genes have been associated with aging and are known to affect multiple cellular pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD). However, the precise molecular mechanisms involved remain unclear. Here, we provide mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major component of the pathognomonic protein inclusions in PD and other synucleinopathies. We found that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition in synucleinopathies.
AB - Sirtuin genes have been associated with aging and are known to affect multiple cellular pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD). However, the precise molecular mechanisms involved remain unclear. Here, we provide mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major component of the pathognomonic protein inclusions in PD and other synucleinopathies. We found that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition in synucleinopathies.
UR - http://www.scopus.com/inward/record.url?scp=85016962065&partnerID=8YFLogxK
U2 - 10.1371/journal.pbio.2000374
DO - 10.1371/journal.pbio.2000374
M3 - Article
C2 - 28257421
AN - SCOPUS:85016962065
SN - 1544-9173
VL - 15
JO - PLoS Biology
JF - PLoS Biology
IS - 3
M1 - e2000374
ER -